467.15EUR+0.18%Mkt Cap: 129.25B $P/E: 31.591d ago
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on spec…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap129.25B $
Enterprise Value122.69B $
Revenue (TTM)13.68B $
Gross Profit11.25B $
Net Income (TTM)4.30B $
Revenue/Share53.81 USD
Last Price467.15 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees6.4K
CountryDE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)31.59
P/E (Forward)—
PEG1.87
EV/EBITDA22.13
EV/Revenue8.97
P/S9.43
P/B6.84
EPS (TTM)14.83
EPS (Forward)—
52W Range
444.8074% of range474.95
52W High474.95 EUR
52W Low444.80 EUR
Profitability
Gross Margin86.24%
Oper. Margin38.05%
EBITDA Margin40.52%
Profit Margin32.94%
ROE21.18%
ROA15.42%
Growth
Revenue Growth12.50%
Earnings Growth8.00%
Cash Flow & Leverage
Operating CF3.95B $
CapEx (TTM)475.65M $
FCF Margin20.88%
FCF Yield2.21%
Net Debt-6.39B $
Net Debt/EBITDA-1.15
Balance Sheet
Debt/Equity0.11
Current Ratio3.19
Quick Ratio2.54
Book Value/Sh68.47 EUR
Cash/Share30.98 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.253.81M
Float252.68M
Insiders0.21%
Institutions98.25%
Technical
SMA 50425.99 (+9.7%)
SMA 200396.30 (+17.9%)
Beta0.30
S&P 52W Chg18.16%
Avg Vol (30d)163
Avg Vol (10d)116
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—